Lecanemab’s Real-World Performance: LEADER Study Offers Insights, But Questions Remain
"While lecanemab showed stability or improvement in nearly 83% of early Alzheimer’s patients in a real-world retrospective study, the absence of a control group means these outcomes cannot be definitively…